In order to test the suggestion that antipsychotic drugs act by blocking dopamine receptors in the brain, the direct effects of such neuroleptic drugs were tested on the stereospecific binding of [3Hldopamine and of [3H]haloperidol to rat brain striata and their subfractions.
The stereospecific component of binding was defined as that amount of [3lH]dopamine or [3Hlhaloperidol bound in the presence of (-)butaclamol (an inactive drug) minus that bound in the presence of (+-butaclamol (a potent neuroleptic drug); 100 nM butaclamol was used for the [3Hlhaloperidol assay, while 1 MuM butaclamol was used for the [3H1dopamine assay. Various antipsychotic drugs inhibited this stereospecific component in both the dopamine and haloperidol assays. These inhibitory potencies correlated with the clinical doses used for controlling schizophrenia. Antipsychotic or neuroleptic drugs are thought to act by blocking dopamine receptors in the nervous system (1) (2) (3) (4) (5) . Hitherto, the evidence for this hypothesis has been indirect. For example, it is known that neuroleptic drugs inhibit dopamine-sensitive adenylate cyclase (5) (6) (7) , increase the firing rate of dopamine neurons (8) , decrease the stimulated release of dopamine from dopaminergic neurons (9) , accelerate the turnover of dopamine (10, 11) , and block the effects of such dopamine-mimetic drugs as amphetamine and apomorphine (11, 12) . The potency of the drugs in these tests is not correlated 1:1 with their potencies in controlling schizophrenia (13, 5) . For example, haloperidol and spiroperidol are 20-100 times more potent clinically than chlorpromazine, yet they are equal to or weaker than chlorpromazine in blocking the dopamine-sensitive adenylate cyclase (5) (6) (7) . The presynaptic coupling-blockade actions of the neuroleptics (9) correlate slightly better with the clinical antipsychotic potencies, but even here the correlation is not 1: 1. Neuroleptics readily concentrate in cell membranes since the drugs are highly surface-active and fat-soluble (14, 15) . This high nonspecific solubility in membranes has prevented the identification of specific binding sites for neuroleptics (16) . The introduction of the new neuroleptic butaclamol, which has an active (+)-enantiomer and an inactive (-)enantiomer (17) (18) (19) (20) , now permits the identification of stereospecific binding sites for neuroleptics along criteria already outlined for the opiate receptor (21, 22 MATERIALS AND METHODS The majority of the experiments were done on homogenates or subcellular fractions of rat brain striatum, since this region contains abundant dopamine (24) , and presumably abundant dopamine and neuroleptic receptors.
1. Preparation of Crude Homogenate of Rat Brain Striatum. Crude homogenates were prepared from rat striata using male albino Wister rats of between 150 and 250 g. The rats were sacrificed by cervical dislocation, and the brains immediately removed and rinsed in ice-cold 0.9% NaCl. The striata (each about 30 mg) were dissected out within 5 min, and 12-16 striata from 6 to 8 animals were pooled for homogenization in 12 ml of ice-cold 0.32 M sucrose for subcellular fractionation, or an ice-cold solution of 15 mM Tris-HC1, 5 mM Na2EDTA, 1.1 mM ascorbate, and 12.5 ,M nialamide, pH 7.4, (buffer A) for the P2 fraction. Buffer A was degassed with N2 for storage. Crude homogenates of the striata were made using a glass homogenizer with a Teflon piston with 0.13-0.18 mm clearance; thq piston, rotating at 500 rpm, was passed up and down 20 times.
2. Preparation of P2 Fraction. The crude homogenate was centrifuged at 1000 X g for 15 min at 40 in a Sorvall RC2B refrigerated centrifuge. The supernatant was saved and the pellet was resuspended in 10 ml of 0.32 M sucrose and recentrifuged at 1000 X g. The pellet (P1) was discarded, and the two supernatants were pooled and centrifuged at 20,000 X g for 30 min at 4°. The supernatant was discarded, and the pellet (P2) was saved for further use.
3. Preparation of Crude Synaptosome Fraction. The P2 fraction was in 6 aliquots layered over a discontinuous sucrose density gradient composed of 4.5 ml of 1.2 M sucrose and 4 ml of 0.8 M sucrose in polycarbonate centrifuge tubes. The tubes were centrifuged at 50,000 X g for 2 hr at 4°in a Beckman L265B Spinco centrifuge, using a swinging bucket rotor. Mil of various solutions of neuroleptics or nonradioactive dopamine, and finally, 200 Mul of the crude synaptosome suspension. All stock solutions were prepared in buffer A and kept 4376 ice-cold. The mixture was incubated on ice for 30 min and then quickly filtered, using a vacuum pump, through 0.45 Mm Millipore filters prewetted with buffer. The underside of each filter was then blotted briefly and its radioactivity 14C and 3H radioactivity was determined in a liquid scintillation vial containing 10 ml of Aquasol (New England Nuclear Corp.) (25) . The radioactive inulin served to correct for the residual supernatant containing the trapped, but unbound, [3H]dopamine left on and in the filter paper as well as between and within the disrupted membranes (26) .
Dopamine Binding
Binding. The majority of the [3H]dopamine assays were done with the P2 fraction and using a centrifugation method (27) . The P2 was resuspended in a buffer consisting of 15 mM Tris-HC1, 5 mM Na2EDTA, and 1.1 mM ascorbate (pH 7.4) (buffer B), and the suspension was incubated at 370 for 1 hr. The fraction was then washed twice by centrifugation at 20,000 X g for 30 min at 40 and resuspension in buffer B. The final suspension, rehomogenized with 20 strokes as before, contained 0.7 mg of protein per ml. The binding of [3H]dopamine was done in 10 X 75 mm glass tubes containing 0.5 ml of 3 nM [3H]dopamine (see Section 4a, above), 0.5 ml of buffer with various concentrations of neuroleptics or butaclamol, and 0.5 ml of the washed P2 suspension. The stock solutions and suspension were kept on ice. The mixture was incubated at 22°for 15 min with Vortex mixing every 5 min. If the incubation was at 40, the absolute amount of binding was reduced by only about 20%; this small temperature effect compares with about a 20-fold difference when one studies dopamine uptake (28, 29) in the higher and more usual dopamine concentration range of 50-800 nM with appropriate cofactors (30) (31) (32) . After incubation, the tubes were centrifuged at 20,000 X g at 40 for 20 min. The supernatant was decanted, and the top of the pellet was rinsed twice with 1 ml of buffer A. The tube was inverted and drained, and the inside walls were wiped with cotton-tipped sticks. One ml of Aquasol was added, and the pellet was dislodged by vigorous mixing. The pellet dissolved within 3 hr and the tube contents were transferred to a liquid scintillation tube with two 1-ml washes of Aquasol. The vials were monitored for 3H. All determinations were made in triplicate at least.
Neuroleptic Binding Assays. (a) Centrifugation
Method for Measuring [3H]Haloperidol Binding. The P2 pellet was resuspended in buffer A, centrifuged, resuspended in the buffer, and incubated at 370 for 60 min with constant shaking; this preincubation step greatly improved the amount of [3H]haloperidol finally bound. The material was then washed twice in buffer A (with 20,000 X g centrifugations) and finally suspended at a protein concentration of 1 mg/ml in buffer A. The [3H]haloperidol binding was done in 10 X 75 mm Pyrex glass test tubes containing 0.5 ml of 0.9-3 nM [3H]haloperidol, 0.5 ml of buffer A containing various concentrations of neuroleptics, butaclamol, or dopamine-mimetic drugs, and 0.5 ml of the washed and preincubated P2 suspension. All samples were in quintuplicate.
After incubating for 30 min at 220, the tubes were centrifuged (20,000 X g for 20 min at 40). Two 0.5-ml aliquots of each supernatant were pipetted into liquid scintillation vials; Aquasol was added and the vials were monitored for 3H. The method for calculating the number of mol of drug adsorbed per mg of protein has been published (33) .
Radioactive haloperidol was obtained by catalytic exchange labeling (using 25 Ci of 3H20; procedure done by New England Nuclear Corp., Boston) and then purifyihg by silica gel thin-layer radiochromatography, using 9:1 chloroform/methanol; final specific activity was 0.1 Ci/mmol. Dr. P. A. J. Janssen, Dr. J. Heykants, and Dr. J. Brugmans generously donated a sample of' [3H]haloperidol specifically labeled in the F-containing ring (0.09 Ci/mmol). [3H]Haloperidol was also obtained from CIS radioactive products (IRE Belgique). The relatively insoluble compounds, such as haloperidol and spiroperidol (spiperone) or apomorphine, were first dissolved at high concentration in ethanol; dilutions were made such that the final ethanol concentration was less than 0.01%.
(b) Dialysis Method for Measuring [3H]Haloperidol
Binding. The binding of [3H]haloperidol was also done by dialysis. Sextuplicate samples of 1 ml each of the washed and pre-incubated P2 fraction (Section 5a, above) were placed in boiled and rinsed dialysis bags (7 cm long and, when flat, 1 cm wide). The bags were placed in 16 X 125 mm culture tubes (15 ml, screw cap with rubber liner) containing 10 ml of 1 nM [3H]haloperidol and 100 nM of either (+)-butaclamol or (-)-butaclamol, and also a third nonradioactive neuroleptic. The tubes were rotated in the dark at 40 for 2.5 days in the presence of penicillin or streptomycin. Duplicate aliquots (0.4 ml) were than taken from inside and outside the bag, placed in 10 ml of Aquasol, and monitored for 3H.
(c) Filter Method for Measuring [3H]Haloperidol Binding. The majority of the [3H]haloperidol binding assays were done using the crude homogenate and a filtration method. The freshly prepared crude homogenate in buffer A was centrifuged at 40,000 X g for 15 min at 40, the supernatant was discarded, and the pellet was rehomogenized in buffer A and preincubated for 1 hr at 370. At this point the suspension was often subdivided and stored at -200. After thawing, the material was rehomogenized and washed once in buffer A.
The binding of [3H]haloperidol was done in triplicate in 22 X 150 mm Pyrex glass boiling tubes, containing aliquots of 100 Ml of 100 nM (+)or (-)-butaclamol, 100,l of another neuroleptic or dopamine-mimetic drug, 200 Ml of 3 nM [3H]haloperidol, and 200 ,ul of the preincubated crude homogenate. The mixture was incubated at 220 with Vortex mixing every 5 min. After 30 min, 12 ml of ice-cold buffer A were injected into the boiling tube with a syringe within 1.5 sec, and the entire contents were poured immediately onto a prewetted glass fiber filter (GF/C, Whatman); filtration, using a vacuum pump, was completed in 1 sec. The filter papers were removed from the filtering manifold (Millipore no. 3025) and placed in 10 ml of Aquasol in a liquid scintillation vial for 3H monitoring. The results were calculated in terms of femtomoles of haloperidol bound per mg of homogenate protein.
RESULTS
The binding of [3H]dopamine to sonicated synaptosomes as well as to the P2 fraction is shown in Fig. 1 The effects of various neuroleptics were tested on the butaclamol stereospecific difference. For example, Fig. 3 shows that the IC5 for chlorpromazine on the stereospecific difference in [3H]dopamine binding was 450 nM where the concentration of either (+)or (-)-butaclamol was 1 ,uM.
Further IC50 values for other neuroleptics, as well as apomorphine, competing for [3H]dopamine binding, are listed in Table 1 (last column) .
Sample data for the competition between various neuroleptics and [3H]haloperidol are shown in Fig. 4 . In this figure the ordinate is expressed in terms of the % of the maximum stereospecific difference [in the presence of 100 nM (+)or (-)-butaclamol]. Examples of two different methods, the dialysis method and the filtration method, are shown in Fig. 4 . In the filtration method, 12 ml of ice-cold buffer A were flooded into the incubation mixture immediately before filtering. This step served to lower the amount of nonspecific adsorption to the glass fiber filters; this amount of nonspecific adsorption was determined in triplicate for every drug concentration tested, and the amount was subtracted from the total binding in the presence of the membranes. This flooding step, however, lowered the free concentration of all drugs, and desorption from the stereospecific binding sites occurred. For example, waiting 15 sec between the addition of buffer A and the filtration completely abolished the stereospecific difference. The effects of various neuroleptics on the binding of [3H]haloperidol to rat striatal fractions. One hundred percent represents the difference in [3H]haloperidol binding in the presence of 100 nM (-)-butaclamol minus that in the presence of 100 nM (+)-butaclamol. The results for chlorpromazine and spiroperidol were obtained on crude homogenates of rat striatum, having a stereospecific difference of 38 fmol/mg and using the filtration assay. The results for haloperidol and molindone were obtained on the P2 fraction, having a stereospecific difference of 185 fmol/mg and using the dialysis method. Six determinations for each point. (29, 37) indicates that, with the exception of reserpine, neuroleptics are more potent in causing the release of [3H]dopamine from striatal synaptosomes than in blocking the uptake. High concentrations of (-)-butaclamol did exert some competition in both the [3H]dopamine and [3H]haloperidol assays; (-)-butaclamol, however, is only maximally 99.5% pure, and the possible presence of 0.5% of (+)-butaclamol might account for the 200-fold difference in potency between the enantiomers. Finally, the effect of temperature on binding was minimal, unlike the temperature dependence of dopamine uptake (28, 29) . Fig. 5 illustrates the IC5o values for the neuroleptics in blocking the stereospecific binding of [3H]dopamine or [3H]haloperidol plotted against the daily clinical doses for controlling schizophrenia (9) . Also included in Fig. 5 is the correlation (from ref. 9) between the clinical doses and the neuroleptic concentrations that block the stimulated release of [3H]dopamine from rat striatal slices. The neuroleptic concentrations that block the stereospecific binding of [3H]dopamine or [3H]haloperidol are lower than those reported in ref. 9 , and these concentrations correlate better with the clinical doses. These conclusions were made in our earlier preliminary communication (4) . We are now using these assays for examining post-mortem brains of schizophrenics.
